Neuronascent, Inc. (NNI) discovers and develops therapies for depression, Down syndrome, post-traumatic stress disorder, Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Our lead candidate for each indication have shown great promise in several cell culture and disease models and show no sign of toxicity or other harmful effects. These, small-molecule, therapeutic candidates all promote new neurons from the brain’s own neuronal stem/progenitor cell populations. Preclinical studies of these candidates are currently under way, in-house and through contract laboratories, to complete the requirements for testing in humans.
Each NNI therapeutic candidate is uniquely optimized to increase neuron numbers in the brain, to improve critical function and to diminish loss of neurons due to disease progression. This ensures that each therapy is optimal for the indication.
News & Events
Apr 2014 Neuronascent Successfully Completes Pre-IND Meeting with FDA for Alzheimer’s Disease Therapeutic. View Press Release
Mar 2014 Neuronascent to participate in the Redefining Early Stage Investment (RESI) Innovation Challenge, an investment meeting in Boston, MA, March 24, 2014.
Jan 2014 Neuronascent, Inc. Announces Issuance of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate. View Press Release
Nov 2013 Neuronascent, Inc. Alzheimer’s Disease Therapeutic Candidate
Selected for Preclinical Safety Testing. View Press Release